The 2017 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Adam J. Fein, Ph.D.
Pembroke Consulting, Inc., and Drug Channels Institute

February 2017

Copyright © 2017 by Pembroke Consulting, Inc. All rights reserved.

This report is protected by copyright law and may not be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed, or resold, in whole or in part, in any form or manner or by any means whatsoever, by any person without prior written consent. This report may be cited in commercial documents with full and appropriate attribution. This report is for informational purposes only and is provided “as is” without any express or implied warranty. The analyses in this report are based solely on information and data that are in the public domain. All conclusions, findings, opinions, and recommendations are based on our own experienced and professional judgment and interpretations given the information available. While all information is believed to be reliable at the time of writing, the information provided here is for reference use only and does not constitute the rendering of legal, financial, commercial, or other professional advice by Pembroke Consulting, Inc., Drug Channels Institute, or the author. Any reliance upon the information is at your own risk, and Pembroke Consulting, Inc., and the author shall not be responsible for any liability arising from or related to the use or accuracy of the information in any way. Pembroke Consulting, Inc., and Drug Channels Institute do not make investment recommendations in this report or otherwise. Nothing in this report should be interpreted as an opinion by Pembroke Consulting, Inc., Drug Channels Institute, or the author on the investment prospects of specific companies.

Drug Channels® is a registered trademark of Pembroke Consulting, Inc.
LICENSE TERMS

This report is protected by copyright law. Unauthorized reproduction or distribution of this report or any portion of it may result in severe civil and criminal penalties and will be prosecuted to the maximum extent of the law. This report may be cited in commercial documents with full and appropriate attribution. Nothing in the license is intended to reduce, limit, or restrict any rights arising from fair use under copyright law or other applicable laws.

If you would like to quote from or otherwise cite the report, here is a suggested sample citation:

ABOUT THE AUTHOR

Adam J. Fein, Ph.D., is the president of Pembroke Consulting, Inc., a management advisory and business research firm based in Philadelphia. He also is the CEO of Pembroke’s Drug Channels Institute, a leading management educator for and about the pharmaceutical industry.

Dr. Fein is one of the country’s foremost experts on pharmaceutical economics and the drug distribution system. Top manufacturers call on Dr. Fein’s insights and judgment to create successful commercial strategies and make better strategic decisions in our evolving healthcare environment.

Dr. Fein’s popular and influential Drug Channels website (www.DrugChannels.net) is the go-to source for definitive and comprehensive industry analysis, delivered with a witty edge. He has published hundreds of academic and industry articles, and he is regularly quoted in such national publications as The Wall Street Journal, The New York Times, and many others.

Dr. Fein earned his doctoral degree from the Wharton School of Business at the University of Pennsylvania and a B.A., summa cum laude, from Brandeis University. He lives in Philadelphia with his wife, Paula, and their two children.

Contact information
Adam J. Fein, Ph.D.
Pembroke Consulting, Inc.
1515 Market Street, Suite 960
Philadelphia, PA 19102
Phone: 215-523-5700
Website: www.PembrokeConsulting.com
Email: afein@pembrokeconsulting.com

Visit the Drug Channels website for the latest industry updates!

www.DrugChannels.net
ABOUT DRUG CHANNELS INSTITUTE

Drug Channels Institute (DCI), a division of Pembroke Consulting, Inc., is a leading provider of specialized management education for and about the pharmaceutical industry.

Drug Channels Institute combines Dr. Fein’s expertise and cutting-edge analysis—such as this 2017 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers—into comprehensive, interactive e-learning modules that offer your team a thorough grounding in crucial industry topics. These online learning tools explain highly complex economic and business data and concepts so that you can:

- Make better decisions to achieve your business goals
- Improve relationships with key accounts
- Understand your customers, channels, and the economics of the U.S. pharmaceutical industry

View a module list at http://drugchannelsinstitute.com/products/e-learning-modules/.

DCI can code and brand any module for your company’s internal Learning Management System. Or you can get started quickly by letting us host your team via our online e-learning portal. DCI’s hosted e-learning modules are instantly viewable on all computer platforms, including iPads.

To learn more about how Drug Channels Institute can help your business, please contact:

Paula Fein, M.S.Ed.
V.P., Business Development
Drug Channels Institute
1515 Market Street, Suite 960
Philadelphia, PA 19102
Phone: 215-523-5700 x11
Website: www.drugchannelsinstitute.com
Email: paula@drugchannelsinstitute.com
INTRODUCTION AND GUIDE TO THIS REPORT

The 2017 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers (known in our previous editions as The Economic Report on Retail, Mail, and Specialty Pharmacies) remains the most comprehensive, fact-based analysis of the evolving drug channels within the U.S. healthcare system.

The new title for this eighth edition reflects the report’s increasingly broad scope. It now integrates information about pharmacy dispensing channels, third-party payers, pharmacy benefit managers (PBMs), patients’ financial contributions, and drug wholesalers. The revised title also acknowledges that many of the largest U.S. pharmacies are owned and operated by PBMs and health plans.

In this definitive, nonpartisan resource, I have synthesized a wealth of statistical data, research studies, financial information, and my own unique business consulting experience. It’s the ultimate guide to the complex web of interactions within the U.S. prescription distribution and reimbursement system. The report will benefit pharmaceutical manufacturers, wholesalers, pharmacists, pharmacy owners, hospital executives, buyers, benefit managers, managed care executives, policy analysts, investors, consultants—anyone who wants to understand and benefit from this ever-changing industry.

Understanding an Evolving Marketplace

Thousands of companies operate within the U.S. pharmacy distribution and reimbursement system, enabling more than 5 billion equivalent prescriptions to be dispensed and paid. Some of the crucial forces reshaping the industry in 2016 include:

- Total prescription dispensing revenues of retail, mail, long-term care, and specialty pharmacies reached $412 billion.

- The pharmacy industry has entered a new period of hypercompetition, driven partly by a plateau in the generic dispensing rate. As the market matures, the pressures on pharmacy profits from generic drugs are intensifying. The consolidation of pharmacy and payer markets shows no sign of slowing.

- Specialty drugs now account for almost one-third of the pharmacy industry’s revenues. Manufacturers and payers, however, are limiting the specialty pharmacies eligible to dispense these expensive medications. These network strategies are shifting specialty dispensing revenues and profits into the largest PBM-owned specialty pharmacies and allowing mail pharmacies to capture more of the industry’s prescription revenues.

- Twenty million people have gained health insurance during the past few years. However, the political outlook for healthcare reform is highly uncertain.
Our table below highlights the primary public companies that operate in the pharmacy distribution and reimbursement system. The 2017 edition of this report contains the latest financial and industry data about the strategies and market positions of the largest public companies: CVS Health, Express Scripts, Rite Aid, Walgreens Boots Alliance, OptumRx, Walmart, and others. Many of these firms are among the largest businesses on the Fortune 500 list.

### Major Public Companies Operating in Pharmacy Drug Channels

<table>
<thead>
<tr>
<th>Company</th>
<th>Stock Ticker</th>
<th>Primary U.S. Channel Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS Health</td>
<td>CVS</td>
<td>Chain drugstore/Pharmacy benefit manager</td>
</tr>
<tr>
<td>Diplomat Pharmacy</td>
<td>DPLO</td>
<td>Specialty pharmacy</td>
</tr>
<tr>
<td>Kroger</td>
<td>KR</td>
<td>Supermarket with pharmacy</td>
</tr>
<tr>
<td>Rite Aid Corporation*</td>
<td>RAD</td>
<td>Chain drugstore/Pharmacy benefit manager</td>
</tr>
<tr>
<td>PharMerica</td>
<td>PMC</td>
<td>Long-term care pharmacy</td>
</tr>
<tr>
<td>Walgreens Boots Alliance</td>
<td>WBA</td>
<td>Chain drugstore</td>
</tr>
<tr>
<td>Walmart Stores, Inc.</td>
<td>WMT</td>
<td>Mass merchant with pharmacy</td>
</tr>
<tr>
<td>AmerisourceBergen Corp.</td>
<td>ABC</td>
<td>Pharmaceutical wholesaler</td>
</tr>
<tr>
<td>Cardinal Health, Inc.</td>
<td>CAH</td>
<td>Pharmaceutical wholesaler</td>
</tr>
<tr>
<td>McKesson Corporation</td>
<td>MCK</td>
<td>Pharmaceutical wholesaler</td>
</tr>
<tr>
<td>Express Scripts, Inc.</td>
<td>ESRX</td>
<td>Pharmacy benefit manager/Mail &amp; specialty pharmacy</td>
</tr>
<tr>
<td>Humana Pharmacy Solutions</td>
<td>HUM</td>
<td>Pharmacy benefit manager/Mail &amp; specialty pharmacy</td>
</tr>
<tr>
<td>OptumRx (UnitedHealth Group)</td>
<td>UNH</td>
<td>Pharmacy benefit manager/Mail &amp; specialty pharmacy</td>
</tr>
</tbody>
</table>

* In October 2015, Walgreens Boots Alliance announced its merger with Rite Aid.  
Source: Pembroke Consulting research

The companies discussed in this report operate within a complex distribution and reimbursement system, illustrated on the next page. This system contains three key channel flows that we discuss in *The 2017 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers*:

- **Product movement**, which traces shipments from pharmaceutical manufacturers to the drug wholesalers that supply pharmacies. Retail, mail, long-term care, and specialty pharmacies mark the final step in which a prescription is dispensed to a patient.

- **Financial flows**, which transfer money from third-party payers to Pharmacy Benefit Managers (PBMs), which in turn reimburse pharmacies. Funds flow to manufacturers via pharmacies, which purchase drugs from wholesalers. Funds flow from manufacturers in the form of rebates to PBMs. The PBMs share a portion of these payments with plan sponsors, reducing net prescription costs. Manufacturers’ rebates to PBMs and other third-party payers do not flow through wholesale or retail channels.

- **Contractual relationships**, which govern the relationships between: 1) payers and PBMs; 2) PBMs and pharmacies; 3) pharmacies and wholesalers; 4) wholesalers and manufacturers; and 5) manufacturers and PBMs.

Later in the report, we revisit the chart below to associate each flow with the corresponding chapters in Section II and Section III that explain and analyze it. That supplemental version of the chart appears as **Exhibit 53** (page 79).
Structure of the 2017 Report

The 2017 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers analyzes the industry in three major sections, comprising ten total chapters. This year’s report retains the structure that we introduced with last year’s edition, so the chapters correspond to those of previous editions. However, many sections have been expanded or reorganized to better cover the latest industry developments. Here are some of the significant updates in the 2017 report:

- A new Preface section provides an integrated overview of the principal themes that recur throughout our analysis. Each theme includes links to relevant chapters and sections within the entire report.

- The data now include long-term care pharmacies. Consequently, market-size figures and growth rates are not comparable with previous figures. We have restated the historical data to reflect this broader market definition. (As always, the current year’s report also incorporates any data restatements made by various reporting organizations.)

- Our analysis and data on specialty drugs and specialty pharmacies have been expanded to account for continued growth in this market segment.

- The PBM industry material now examines the strategies and position of the largest companies.
New analysis examines factors affecting pharmacy profits. These include Direct and Indirect Remuneration (DIR) fees, drug price inflation, and changes in wholesalers’ pricing strategies.

We have streamlined and refocused the material on wholesalers so that it more directly addresses issues related to pharmacy economics. A broader and deeper analysis of the pharmaceutical wholesaling market is available in our companion *2016-17 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors*.

Here is a summary of the report’s major sections and chapters:

**SECTION I: THE U.S. PHARMACY INDUSTRY**

- **Chapter 1: Industry Overview** (page 7) has been significantly reorganized for the 2017 edition and provides a foundation for the entire report. It defines the industry and its regulatory framework, describes the different products and prescriptions that a pharmacy dispenses, delineates among different pharmacy industry participants, and quantifies differences among dispensing formats. This chapter now includes our updated analysis of retail clinics and pharmacist-provided clinical services, including medication therapy management services.

- **Chapter 2: Pharmacy Industry Market Structure** (page 32) analyzes the industry’s prescription and revenue growth trends. It identifies the largest pharmacies based on prescription revenues. It then analyzes recent market share trends for each dispensing format and for the major national companies.

- **Chapter 3: Specialty Drugs and Specialty Pharmacies** (page 50) provides a comprehensive overview of the pharmacies dispensing specialty medications. It includes our exclusive analysis of national market share for pharmacy-dispensed specialty drugs. It also provides a competitive analysis of the various organizations that compete to dispense specialty medications. The chapter also reviews the channel strategies that pharmaceutical manufacturers use for specialty drugs and considers the outlook for pharmacy-dispensed biosimilars.

**SECTION II: THIRD-PARTY PAYMENT AND PHARMACY BENEFITS**

- **Chapter 4: Payment and Spending for Prescription Drugs** (page 80) examines the primary payers for prescription drugs at retail, mail, long-term care, and specialty pharmacies. It analyzes recent changes in the payer mix and spending on traditional vs. specialty drugs. It presents the outlook for net prescription drug spending, gross spending changes on traditional and specialty drugs, and the future payer mix. Chapter 4 also provides our updated projections for the pharmacy industry’s product mix and revenues in 2021.
• **Chapter 5: Pharmacy Benefit Management** (page 95) has been expanded and reorganized for the 2017 edition. It identifies the services of pharmacy benefit managers (PBMs) and describes the structure of the PBM industry. The chapter explores rebate negotiations with manufacturers, explains trends in gross-to-net drug prices, and reveals the impact of rebates on third-party payers. Chapter 5 also describes the relationship between PBMs and the pharmacies that participate in a PBM’s network, reviews how Pharmacy Services Administration Organizations (PSAOs) intermediate between retail pharmacies and PBMs, and explains how plan sponsors compensate PBMs for benefit management services.

• **Chapter 6: Consumer Copayments and Coinsurance** (page 120) analyzes the benefit designs and plan structures that determine patients’ out-of-pocket spending for the major third-party payers: employer-sponsored health plans, Health Insurance Marketplace (HIM) plans, Medicare Part D, and Medicaid. We also explore the growth of plans with prescription deductibles and provide new data on manufacturers’ copay offset programs for specialty drugs.

• **Chapter 7: Narrow Pharmacy Networks** (page 136), which was introduced in the 2016 edition, analyzes the structure, utilization, and economics of narrow network models. We explain the use and economics of narrow networks for retail pharmacies in commercial health plans and Medicare Part D. We review the use of mail and retail pharmacies as narrow network options for maintenance prescriptions. This chapter also evaluates payer-defined networks for specialty drug dispensing.

**SECTION III: DRUG CHANNEL ECONOMICS**

• **Chapter 8: Prescription Reimbursement by Third-Party Payers** (page 151) explains the current formulas and methodologies for computing a pharmacy’s revenue from brand-name, generic, and specialty prescriptions. This chapter compares traditional list price methods with acquisition-cost reimbursement approaches. We also review the economics of mail vs. retail pharmacies for payers and consumers. The chapter concludes by illustrating how prescription reimbursement, formulary rebates, and consumer copayments affect a plan sponsor’s net costs for a prescription.

• **Chapter 9: Relationships With Pharmaceutical Wholesalers** (page 167) explores pharmacies’ interactions with their primary wholesale suppliers of drugs. It explains wholesalers’ channel roles and services, identifies the largest wholesale suppliers, and analyzes how wholesalers affect pharmacies’ acquisition costs for drugs. We present our latest data on pharmacy group purchasing organizations and the generic sourcing relationships between wholesalers and large pharmacies.

• **Chapter 10: Pharmacy and Prescription Profitability** (page 182) unites the reimbursement and cost discussion from Chapters 8 and 9 by presenting the latest data on pharmacy and prescription profitability. This chapter documents overall drugstore
profitability, pharmacy margins for prescriptions from different dispensing formats, profit differences between brand and generic prescriptions, and PBMs’ per-prescription profits from network and mail pharmacies. Chapter 10 includes new material on per-prescription payments that pharmacies make to PBMs and health plans. These include DIR fees and other performance-related payments. Finally, we consider pharmacy profits in the 340B Drug Pricing Program.

Using the 2017 Report

_The chapters are self-contained and do not need to be read in order._ We include extensive internal references to help you navigate the entire document and customize it to your specific needs. There are more than 400 endnotes, most of which have hyperlinks to original source materials. The report also includes a list of the Acronyms and Abbreviations used within it.

Please note that highlighted internal references are clickable hyperlinks in the PDF document. After clicking a link, use the following shortcuts to return to your previous location in the document:

- Windows: ALT+Left Arrow
- Mac: Command+Left Arrow

To search the entire PDF document for every occurrence of a word or phrase, use the following keyboard shortcuts:

- Windows: Shift+CTRL+F
- Mac: Shift+Command+F

As always, I welcome your feedback. Please contact me if you have any questions or comments about _The 2017 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers._

Adam J. Fein
February 2017

P.S. Click here for post-publication errata.
## CONTENTS

**PREFACE: INDUSTRY TRENDS AND KEY REPORT THEMES** ................................................................. 1

**SECTION I: THE U.S. PHARMACY INDUSTRY** .................................................................................. 6

Chapter 1: Industry Overview .................................................................................................................. 7

1.1. Pharmacy Fundamentals .................................................................................................................. 7

1.1.1. Defining the Practice of Pharmacy ............................................................................................... 7

1.1.2. Pharmacies and the Drug Supply Chain Security Act ................................................................. 8

1.2. The Products That Pharmacies Dispense ......................................................................................... 9

1.2.1. Brand vs. Generic Drugs .............................................................................................................. 10

1.2.2. Traditional vs. Specialty Drugs .................................................................................................... 11

1.2.3. Average U.S. Per-Prescription Revenues ................................................................................... 15

1.2.4. Top Traditional Therapy Classes and Average Prescription Costs ............................................ 15

1.2.5. Top Specialty Therapy Classes and Average Prescription Costs .............................................. 16

1.3. Pharmacy Industry Participants ..................................................................................................... 17

1.3.1. Pharmacy Dispensing Formats .................................................................................................. 17

1.3.2. Differences Among Outpatient Retail Dispensing Formats ......................................................... 19

1.3.3. Pharmacist Employment and Salaries ......................................................................................... 23

1.4. Healthcare and Clinical Services ................................................................................................... 25

1.4.1. Retail Clinics ............................................................................................................................... 25

1.4.2. Clinical Services and Medication Therapy Management (MTM) ............................................ 28

1.4.3. Immunization ............................................................................................................................. 31

Chapter 2: Pharmacy Industry Market Structure .................................................................................. 32

2.1. Industry Trends ............................................................................................................................... 32

2.1.1. Total and 30-Day Equivalent Prescriptions ............................................................................... 32

2.1.2. Prescription Dispensing Revenues ............................................................................................. 34

2.2. National Prescription Dispensing Market Share, by Company .................................................... 35

2.3. Trends by Dispensing Format ......................................................................................................... 37

2.3.1. Revenues, Prescriptions, and Number of Pharmacies: 2011 to 2016 Trends .......................... 37

2.3.2. Market Changes in 2016 ............................................................................................................. 39

2.3.3. National Retail Chains ............................................................................................................... 40
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.3.4. Regional Drugstore Chains</td>
<td>43</td>
</tr>
<tr>
<td>2.3.5. Independent Pharmacies</td>
<td>44</td>
</tr>
<tr>
<td>2.3.6. Mail Pharmacies</td>
<td>47</td>
</tr>
<tr>
<td>Chapter 3: Specialty Drugs and Specialty Pharmacies</td>
<td>50</td>
</tr>
<tr>
<td>3.1. Specialty Pharmacies</td>
<td>50</td>
</tr>
<tr>
<td>3.1.1. Defining Specialty Pharmacy</td>
<td>50</td>
</tr>
<tr>
<td>3.1.2. Clinical and Data Services</td>
<td>51</td>
</tr>
<tr>
<td>3.1.3. Accreditation</td>
<td>53</td>
</tr>
<tr>
<td>3.2. Specialty Pharmacy Market Structure</td>
<td>54</td>
</tr>
<tr>
<td>3.2.1. Specialty Industry Revenues and Number of Specialty Pharmacies</td>
<td>54</td>
</tr>
<tr>
<td>3.2.2. National Market Share for Specialty Dispensing, by Company</td>
<td>56</td>
</tr>
<tr>
<td>3.2.3. Mergers and Acquisitions Among Specialty Pharmacies in 2016</td>
<td>57</td>
</tr>
<tr>
<td>3.3. Trends by Specialty Dispensing Format</td>
<td>59</td>
</tr>
<tr>
<td>3.3.1. Overview</td>
<td>59</td>
</tr>
<tr>
<td>3.3.2. Pharmacy Benefit Managers and Health Plans</td>
<td>61</td>
</tr>
<tr>
<td>3.3.3. Independent Specialty Pharmacies</td>
<td>62</td>
</tr>
<tr>
<td>3.3.4. Retail Community Pharmacies</td>
<td>64</td>
</tr>
<tr>
<td>3.3.5. Hospitals and Health Systems</td>
<td>66</td>
</tr>
<tr>
<td>3.3.6. Physician Practices</td>
<td>68</td>
</tr>
<tr>
<td>3.3.7. Pharmaceutical Wholesalers</td>
<td>70</td>
</tr>
<tr>
<td>3.4. Manufacturer Channel Strategies for Specialty Drugs</td>
<td>71</td>
</tr>
<tr>
<td>3.4.1. Manufacturer-Defined Dispensing Networks</td>
<td>71</td>
</tr>
<tr>
<td>3.4.2. Manufacturers’ Distribution Strategies for Specialty Drugs</td>
<td>73</td>
</tr>
<tr>
<td>3.4.3. Specialty Hub Services</td>
<td>74</td>
</tr>
<tr>
<td>3.5. The Outlook for Pharmacy-Dispensed Biosimilars</td>
<td>75</td>
</tr>
<tr>
<td>SECTION II: THIRD-PARTY PAYMENT AND PHARMACY BENEFITS</td>
<td>79</td>
</tr>
<tr>
<td>Chapter 4: Payment and Spending for Prescription Drugs</td>
<td>80</td>
</tr>
<tr>
<td>4.1. U.S. Healthcare Spending</td>
<td>80</td>
</tr>
<tr>
<td>4.1.1. Enrollment in Health Insurance</td>
<td>80</td>
</tr>
<tr>
<td>4.1.2. Prescription Drugs and U.S. Healthcare Spending</td>
<td>81</td>
</tr>
<tr>
<td>4.2. Payer and Spending Trends for 2015</td>
<td>83</td>
</tr>
</tbody>
</table>
Chapter 6: Consumer Copayments and Coinsurance ................................................................. 120
  6.1. Employer-Sponsored Health Plans .............................................................................. 121
  6.2. Health Insurance Marketplace Plans ......................................................................... 123
  6.3. Medicare Part D ....................................................................................................... 124
  6.4. Medicaid ............................................................................................................... 127
  6.5. Prescription Drug Deductibles .................................................................................. 128
  6.6. Manufacturer Copayment Offset Programs ......................................................... 132
Chapter 7: Narrow Pharmacy Networks ............................................................................. 136
  7.1. Overview of Pharmacy Benefit Network Models .................................................... 136
    7.1.1. Network Options .............................................................................................. 136
    7.1.2. The Appeal of Narrow Networks ..................................................................... 138
  7.2. Retail Pharmacy Networks ...................................................................................... 140
    7.2.1. Preferred Retail Networks in Medicare Part D ............................................... 140
    7.2.2. Narrow Retail Networks in Commercial and Other Plans ................................ 144
    7.2.3. Narrow Networks for Maintenance Prescriptions ......................................... 145
  7.3. Payer-Defined Specialty Dispensing Networks ......................................................... 147
SECTION III: DRUG CHANNEL ECONOMICS ....................................................................... 150
Chapter 8: Prescription Reimbursement by Third-Party Payers ........................................ 151
  8.1. The Basics of Prescription Reimbursement .............................................................. 151
    8.1.1. Estimated Acquisition Cost (EAC) .................................................................. 152
    8.1.2. Dispensing Fees ............................................................................................. 153
    8.1.3. Service and Data Fees .................................................................................... 154
  8.2. Reimbursement for Brand-Name and Specialty Prescriptions ................................ 156
    8.2.1. Wholesale Acquisition Cost (WAC) and Average Wholesale Price (AWP) List Prices .......... 156
    8.2.2. Average AWP Discounts for Pharmacy Reimbursement ............................... 157
    8.2.3. Why Mail Pharmacies Accept Lower Reimbursements .................................... 159
  8.3. Reimbursement for Generic Prescriptions ................................................................. 160
    8.3.1. Challenges for List-Price Benchmarks ........................................................... 160
    8.3.2. Maximum Allowable Cost (MAC) Limits ...................................................... 161
    8.3.3. Regulations and Laws Regarding MAC Limits ............................................. 161
    8.3.4. Medicaid and Federal Upper Limits ............................................................. 162
Chapter 8: How Prescription Reimbursement, Formulary Rebates, Consumer Copayments, and PBM Expenses Affect Plan Sponsor Costs

Chapter 9: Relationships With Pharmaceutical Wholesalers

Chapter 10: Pharmacy and Prescription Profitability
10.4. Per-Prescription Fees and Payments ................................................................. 197
  10.4.1. DIR Fees in Medicare Part D Networks .................................................. 198
  10.4.2. Performance-Based Pharmacy Networks .................................................. 199
  10.4.3. Controversy Over Per-Prescription Fees .................................................. 201
10.5. Pharmacy Profits from the 340B Drug Pricing Program .................................. 202
  10.5.1. Overview of the 340B Program and Contract Pharmacies .......................... 202
  10.5.2. Flow of Funds With a Contract Pharmacy ............................................... 203
  10.5.3. Pharmacy and Covered Entity Profits from 340B Prescriptions ............... 205

Acronyms and Abbreviations .................................................................................. 207
Endnotes .................................................................................................................. 208
# LIST OF EXHIBITS

Exhibit 1: Timeline of DSCSA Requirements for Pharmacies (Dispensers), 2013-2023 .............................................. 8
Exhibit 2: Unbranded and Branded Generics, Share of U.S. Prescriptions, 2005-2021F ............................................ 10
Exhibit 3: Specialty Drug Prescriptions As a Percentage of Pharmacy Industry Revenues, 2010-2016 ................. 12
Exhibit 4: Generic Dispensing Rate, Top Traditional vs. Specialty Therapy Classes, 2015 .............................. 13
Exhibit 5: Factors Determining Health Plan Classification As Specialty Therapy ............................................. 13
Exhibit 6: Top 10 Traditional Therapy Categories and Average Prescription Cost, 2015 ..................................... 16
Exhibit 7: Top 10 Specialty Therapy Categories and Average Prescription Cost, 2015 ................................. 16
Exhibit 8: Long-Term Care Pharmacy, Customer Mix, by Pharmacy Ownership, 2015 .............................. 18
Exhibit 9: Average Revenue per 30-Day Equivalent Prescription, by Dispensing Format, 2010-2016E ........ 19
Exhibit 10: Average Annual Number of Prescriptions per Pharmacy, by Retail Dispensing Format, 2016 ... 20
Exhibit 11: Prescriptions Dispensed per Location, by Dispensing Format, 2006-2016 ........................................ 21
Exhibit 12: Average Annual Prescription Revenue per Pharmacy Outlet, by Retail Dispensing Format, 2016 .... 21
Exhibit 13: Top Three Reasons for Pharmacy Selection, by Dispensing Format, 2016 ..................................... 22
Exhibit 14: Customer Satisfaction With Pharmacies, by Dispensing Format, 2016 ........................................... 22
Exhibit 15: Pharmacist Employment and Salary, by Dispensing Format, 2015 .................................................. 23
Exhibit 16: Pharmacists and Healthcare Workers, Change in Annual Average Salary, by Employer, 2011-2015 ...... 24
Exhibit 17: Pharmacist Employment, by Dispensing Format, 2015 vs. 2024 ....................................................... 24
Exhibit 18: Number of U.S. Retail Clinics, 2004-2016 ......................................................................................... 25
Exhibit 19: Location of Retail Clinics, by Chain, 2017 ......................................................................................... 26
Exhibit 20: Providers of Medication Therapy Management Services, Medicare Part D, 2016 .................. 29
Exhibit 22: Pharmacists’ Rating of Workload, by Dispensing Format, 2004 vs. 2014 ....................................... 31
Exhibit 23: Adult Influenza Vaccination, by Place of Vaccination, 2012-13 vs. 2016-17 ............................... 31
Exhibit 24: Total U.S. Pharmacy Industry Prescription Revenues, Prescriptions, and Locations, by Dispensing Format, 2016 ................................................................. 32
Exhibit 25: Prescriptions, Annual Total and Growth, 2011-2016E ............................................................... 33
Exhibit 26: 30-Day Equivalent Prescriptions, Annual Total and Growth, 2011-2016E ................................ 33
Exhibit 27: 90-Day Prescriptions As a Percentage of Total Prescriptions, by Dispensing Format, 2011 vs. 2016E .... 34
Exhibit 28: Pharmacy Industry Prescription Revenues, Annual Total and Growth, 2011-2016E ............... 35
Exhibit 29: Largest 15 U.S. Pharmacies, by Total Prescription Revenues, 2016 ............................................... 36
Exhibit 30: Total Change in 30-Day Equivalent Prescriptions Dispensed and Prescription Revenues, by Pharmacy Format, 2011-2016E ................................................................. 38
Exhibit 31: Number of Pharmacies, by Dispensing Format, 2011 vs. 2016 ..................................................... 38
Exhibit 32: Number of 30-Day Equivalent Prescriptions, by Dispensing Format, 2015 vs. 2016E .............. 39
Exhibit 33: Prescription Dispensing Revenues, by Dispensing Format, 2015 vs. 2016E ............................ 40
Exhibit 34: Year-Over-Year Change in Same-Store Prescription Count, 2013-2016
Exhibit 35: Largest Regional Chain Drugstores, by Total Prescription Revenues, 2015
Exhibit 36: Number of Independent Pharmacies, 1991-2016
Exhibit 37: Pharmacy Franchise and Marketing Programs, 2016
Exhibit 38: Share of Mail Pharmacy Dispensing Revenues, by Company, 2016
Exhibit 39: Specialty Prescription Dispensing Revenues, Annual Total and Growth, 2011-2016E
Exhibit 40: Number of Pharmacy Locations With Specialty Pharmacy Accreditation, URAC vs. ACHC, December 2016
Exhibit 41: Locations With URAC Specialty Pharmacy Accreditation, 2008-2016
Exhibit 43: Specialty Pharmacy Mergers and Acquisition Transactions, 2008-2015
Exhibit 44: Pharmacy Locations With Specialty Pharmacy Accreditation, by Corporate Ownership, 2015 vs. 2016
Exhibit 45: Specialty Drug Prescription Revenues, by Dispensing Format, 2016
Exhibit 46: Fastest-Growing Private Specialty Pharmacies, 2015
Exhibit 47: Retail Chains With Specialty Pharmacy Businesses, 2016
Exhibit 48: Hospital Systems’ Specialty Pharmacy Capabilities and Intentions, 2016
Exhibit 49: Patient-Administered Oncology Volume, by Dispensing Channel, 2015
Exhibit 50: Alternative Channels to Specialty Pharmacies in Limited Dispensing Networks
Exhibit 51: Leading Specialty Hub Services Providers, 2016
Exhibit 52: Number of U.S. Biosimilar Development Programs, 2013 to 2016
Exhibit 53: Chapter Coverage of Flows in the U.S. Distribution and Reimbursement System
Exhibit 54: Health Insurance Enrollment, by Payer, 2005 vs. 2015
Exhibit 55: Prescription Expenses per Person, by Age, 2014
Exhibit 56: Share of U.S. National Health Expenditures, by Major Spending Category, 1974-2024
Exhibit 57: Outpatient Prescription Drugs As a Share of U.S. National Health Expenditures, by Payer, 2005 vs. 2015
Exhibit 58: Source of Payment for Outpatient Prescription Drug Expenditures, 2015
Exhibit 59: Change in Net Spending for Outpatient Prescription Drugs, by Payer, 2014 vs. 2015
Exhibit 61: Change in Drug Spending, Traditional vs. Specialty Drugs, by Payer, 2015
Exhibit 62: Change in Gross Pharmacy Benefit Drug Spending, Traditional vs. Specialty Drugs, 2002 to 2015
Exhibit 63: Components of Changes in Traditional Drug Spending, by Payer, 2015
Exhibit 64: Components of Changes in Specialty Drug Spending, by Payer, 2015
Exhibit 65: Brand Revenues Lost to Generic Launches, 2009 to 2019
Exhibit 66: Pharmacy Industry Prescription Revenues, Traditional vs. Specialty Drugs, 2011-2021
Exhibit 67: Projected Growth Rates in National Health and Outpatient Prescription Drug Expenditures, 2012-2025
Exhibit 68: Source of Payment for Outpatient Prescription Drug Expenditures, 2025 (July 2016 CMS Projection)
The 2017 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Exhibit 102: Average Annual Benefit for Copayment Offset Program, by Specialty Therapy Class, 2016

Exhibit 103: Employer Views on Specialty Copayment Assistance Programs, 2016

Exhibit 104: Summary of Pharmacy Benefit Network Design Options


Exhibit 106: Medicare Part D PDPs With Preferred Pharmacy Networks, 2011-2017

Exhibit 107: Participation As Preferred Cost Sharing Pharmacies in Selected Medicare Part D PDPs, by Retail Chain, 2017

Exhibit 108: Participation As Preferred Cost Sharing Pharmacies in Selected Medicare Part D PDPs, by PSAO, 2017

Exhibit 109: Retail Pharmacy Network Design in Employer-Sponsored Plans, 2013 to 2016


Exhibit 112: Employer Perceptions of Specialty vs. Retail Pharmacies, 2015

Exhibit 113: Payer Methodologies for Computing a Pharmacy’s Estimated Acquisition Cost

Exhibit 114: Average Dispensing Fee for Brand-Name Prescriptions at Retail Pharmacies, 1999 to 2015

Exhibit 115: AWP Reimbursement and Copayments for Brand-Name Prescriptions, by Dispensing Format, 2015/16

Exhibit 116: Reimbursement of Specialty Drug Prescriptions at Specialty Pharmacies, Percentage of Average Wholesale Price, 2006 to 2015

Exhibit 117: AWP Reimbursement and Copayments for Generic Prescriptions, by Dispensing Format, 2015/16

Exhibit 118: Acquisition Cost Methodologies for Pharmacy Reimbursement Used by State Medicaid Programs, 2016

Exhibit 119: Example of Brand-Name Prescription Economics for a Third-Party Payer

Exhibit 120: Follow the Dollar Flows for Brand-Name Prescription Economics


Exhibit 122: Full-Line Wholesaler Sales to Retail Chain Warehouses, 2008 to 2015

Exhibit 123: Largest U.S. Pharmacies and Their Primary Wholesale Suppliers, 2016

Exhibit 124: Determination of a Pharmacy’s Brand-Name Drug Acquisition Cost from a Wholesaler

Exhibit 125: Pharmacy Buying Groups and Primary/Preferred Wholesaler Relationships, by Participating Pharmacies, 2016


Exhibit 127: Overall Gross Margins for Chain and Independent Drugstores, 1993-2014

Exhibit 128: Total Gross Profits for Chain and Independent Drugstores, 2006-2014

Exhibit 129: Overall Gross Margins for Chain Drugstores, by Company, 2015

Exhibit 130: Example of Brand-Name Prescription Economics for a Pharmacy

Exhibit 131: Independent Pharmacies, Average Per-Prescription Gross Profits and Margins, 2011-2016

Exhibit 132: Diplomat Pharmacy, Average Per-Prescription Gross Profits and Margins, 2011-2016
Exhibit 134: PBM, Average Per-Prescription Gross Profit and Gross Margin, by Dispensing Channel and Drug Type, 2016

Exhibit 135: Average Year-Over-Year Change in List Price, Top Best-Selling Brand-Name Drugs, 2005-2016

Exhibit 136: Illustrative Effect of Brand-Name List Price Increases on a Prescription’s Gross Profit

Exhibit 137: Lifecycle of Per-Prescription Gross Profits, Brand vs. Multisource Generic

Exhibit 138: Average Generic Price Relative to Brand Price After Loss of Exclusivity

Exhibit 139: Examples of Pharmacy Acquisition Cost, Brand-Name vs. Generic Drug, 2016

Exhibit 140: Average Year-Over-Year Change in Pricing of Mature Generic Drugs, 2014-2016

Exhibit 141: 340B Contract Pharmacy Locations, by Chain, 2016

Exhibit 142: Flow of Funds and Product for a 340B Contract Pharmacy Network

Exhibit 143: Hypothetical Profits for a 340B Entity From a Third-Party Prescription Dispensed by a 340B Contract Pharmacy